Switch to ADA Accessible Theme
Close Menu
Columbia Injury Lawyers > Blog > Products Liability > FDA Recalls More Than 25,000 Bottles of Blood Pressure Medication Over Quality Concerns

FDA Recalls More Than 25,000 Bottles of Blood Pressure Medication Over Quality Concerns

__Recall

Many Americans take one or more medications on a daily basis to manage chronic conditions. Unfortunately, drugs can sometimes be recalled for various reasons.

The Food and Drug Administration (FDA) has announced a nationwide recall involving more than 25,000 bottles of a commonly prescribed blood pressure medication after laboratory testing revealed problems with the tablets’ ability to dissolve properly.

The recalls involve 25-milligram chlorthalidone tablets manufactured by Inventia Healthcare Limited. The medication is a diuretic, commonly known as a water pill, used to treat high blood pressure and reduce excess fluid retention.

According to FDA enforcement reports, the manufacturer initiated two voluntary recalls in 2026. The first, announced June 5, involved 11,460 bottles. A second recall, initiated September 3, affected another 13,567 bottles. Combined, the recalls cover 25,027 bottles.

The FDA classified both recalls as Class II, meaning exposure to the affected medication could cause temporary or medically reversible health problems, while the likelihood of serious adverse health consequences is considered low.

Why Was the Blood Pressure Medication Recalled?

The recall was prompted by the tablets’ failure to meet established dissolution specifications during laboratory testing. Dissolution testing measures how quickly a medication breaks down in a liquid environment and releases its active ingredients. This process is important because a tablet must dissolve appropriately for the body to absorb the medication as intended. Inadequate dissolution could interfere with how much chlorthalidone enters the bloodstream, potentially reducing its effectiveness in controlling blood pressure.

Testing associated with the earlier June recall identified two quality concerns. The tablets contained 91.5% of the labeled amount of chlorthalidone, slightly below the required minimum of 92%. Additionally, an average of 78% of the medication dissolved during testing, falling short of the required 80%.

Which Medications Are Included in the Recall?

The recalls affect three batches of chlorthalidone tablets, USP, 25 mg. The affected medications were distributed in bottles containing either 100 or 1,000 tablets.

The recalled products include:

  • September 2026 recall: Batch RISA24002, involving 13,567 bottles containing 100 tablets each.
  • June 2026 recall: Batch RISA24001, involving 100-tablet bottles.
  • June 2026 recall: Batch RISB24002, involving 1,000-tablet bottles.

All three batches have an expiration date of April 2027. The National Drug Code (NDC) associated with the affected products is 64980-599-01 for the 100-tablet bottles and 64980-599-10 for the 1,000-tablet bottles.

People who take chlorthalidone should not automatically stop taking their medication if they discover that their prescription may be affected. Suddenly discontinuing blood pressure medication without medical guidance can create additional health risks. Patients should contact the pharmacy where they filled their prescriptions to verify the manufacturer, lot number, and NDC. Those who experience concerning symptoms or believe their medication is not controlling their blood pressure should contact their healthcare providers.

Contact Us Today

Sometimes medications can be defective and not work properly. This can lead to health issues in some cases.

Review your case with the Columbia products liability lawyers from Simmons Law Firm. Let us assess the situation and work to pursue the full range of damages available. Call (803) 779-4600 or fill out the online form to schedule a consultation.

Source:

https://www.healthline.com/health-news/blood-pressure-medication-nationwide-recall-fda

Facebook Twitter LinkedIn